<DOC>
	<DOCNO>NCT00143000</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy peginterferon alfa-2a 40KD combination therapy ribavirin interferon naïve patient chronic hepatitis C virus infection genotype 2 3 give 12 week non-inferior 24 week .</brief_summary>
	<brief_title>Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon Ribavirin Hepatitis C Virus ( HCV ) Genotype 2 3</brief_title>
	<detailed_description>Primary Objective Study : To demonstrate efficacy peginterferon alfa-2a 40KD combination therapy ribavirin interferon naïve patient chronic hepatitis C ( CHC ) virus infection genotype 2 3 give 12 week non-inferior 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female patient ≥18 year age Serologic evidence chronic hepatitis C infection antiHCV antibody test Serum HCVRNA quantifiable &gt; 600 IU/mL Roche AMPLICOR HCV MONITOR® Test , v2.0 . HCV genotype 2 3 infection confirm within past 2 year precede initiation test drug dosing . Elevated serum ALT activity document least one occasion within past 12 month precede initiation test drug dosing . Chronic liver disease consistent chronic hepatitis C infection biopsy ( obtain within past 2 year ) judge local pathologist . Compensated liver disease ( ChildPugh Grade A clinical classification ) Patients cirrhosis transition cirrhosis must abdominal ultrasound , CT scan , MRI scan without evidence hepatocellular carcinoma serum AFP &lt; 100 ng/mL within 2 month randomization Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile male females receive ribavirin must use effective contraception treatment 6 month treatment end Women ongoing pregnancy breast feed IFN ribavirin therapy previous time Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) *6 month prior first dose study drug Any investigational drug ≤6 week prior first dose study drug . HCV genotype 1 , 4 , 5 6 infection . Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , antiHIV Ab Evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History evidence decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screen Serum creatinine level &gt; 2 mg/dl ( &gt; 124 µmol/L ) creatinine clearance &lt; 50 ml/minute screen Severe psychiatric disease , especially depression , judge treat physician . History severe seizure disorder current anticonvulsant use History immunologically mediate disease , severe chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study Thyroid dysfunction adequately control ( TSH T4 level normal range ) Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) clinically relevant ophthalmological disorder due diabetes mellitus hypertension Evidence drug abuse ( include excessive alcohol consumption ) accordance local therapeutic tradition . Inability unwillingness provide inform consent abide requirement study Male partner woman pregnant Ηemoglobin &lt; 11.3 g/dL ( &lt; 7.0 mmol/L ) woman &lt; 12.9 g/dL ( &lt; 8.0 mmol/L ) men screen . Any patient increase baseline risk anemia ( e.g . thalassemia , spherocytosis , history GI bleeding , etc ) anemia would medically problematic Patients document presumed coronary artery disease cerebrovascular disease enrol , judgment investigator , acute decrease hemoglobin 4 g/dL ( may see ribavirin therapy ) would welltolerated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
</DOC>